Coherus Oncology: 3 Key Takeaways for Long-Term Investors
On its third quarter of 2026 earnings call, held on Nov. 9, 2026, Coherus Oncology (NASDAQ:CHRS) announced a 30% workforce cut to lower operating expenses while focusing development on its primary cancer drug candidates. The business faces a cash runway of less than 12 months, making spending discipline and sales execution vital for long-term survival. Three things management said stand out. Management is cutting workforce from about 140 to 100 full-time employees, or FTEs, this month to streamline operations after exiting its biosimilar business. This rightsizing trims quarterly costs by $6 million to $7 million, lowering the revenue LOQTORZI, its approved cancer drug, needs to cover nondevelopment core cash burn from $30 million to $35 million down to $25 million to $30 million per quarter. Coherus Oncology is narrowing clinical efforts for tagmokitug, its clinical-stage targeted antibody candidate, toward esophageal cancer to create a faster regulatory path. Early trial results in combination with toripalimab demonstrated responses in both main tumor cell types, establishing a go-forward dose of 700 milligrams for upcoming U.S. Food and Drug Administration discussions. Continue reading